Healthcare & Pharmaceuticals
Sanofi trial failure halts work on breast cancer treatment amcenestrant
Healthcare & Pharmaceuticals · August 17, 2022 · 10:12 AM PDT
Sanofi has stopped further work on amcenestrant, a treatment once seen to have strong commercial potential in breast cancer, after a second trial failure dealt a major blow to the French healthcare company's development prospects.
Healthcare & Pharmaceuticals
Bluebird's $2.8 mln gene therapy becomes most expensive drug after U.S. approval
Mrinalika Roy
5:40 PM PDT
Plaintiff in first Zantac lawsuit set for trial drops case
11:54 AM PDT
U.S. judge reinstates North Carolina ban on late-term abortions
5:31 PM PDT
FDA says faulty Philips device reports accelerating as CEO departs
10:01 AM PDT
U.S. CDC plans to focus on public health response after pandemic failings
12:30 PM PDT
CVS, Walmart and Walgreens ordered to pay $650.6 million to Ohio counties in opioid case
11:43 AM PDT
South Carolina top court puts abortion ban on hold as it hears challenge
5:49 PM PDT
Healthcare & Pharmaceuticals
Russia's daily COVID cases cross 30,000 for first time since mid-March
10:29 AM PDT
Endo files for bankruptcy as U.S. opioid litigation drags
10:00 AM PDT
Factbox: Latest on the worldwide spread of the coronavirus
9:39 AM PDT
U.S. approves sale of over-the-counter hearing aids
August 16, 2022
Takeda's dengue vaccine expected to be approved in Indonesia soon -Nikkei
2:17 AM PDT
Baby formula supplies improving, say U.S. retailers Walmart and Target
August 16, 2022
China reports 3,036 new COVID cases for Aug 16 vs 2,526 day earlier
August 16, 2022
U.S. FDA gets over 48,000 reports of faulty Philips respiratory devices in May-July
August 16, 2022
Bill Gates, South Korea expand global health partnership
August 16, 2022
WHO vows nothing 'ridiculous' as public submits ideas to rename monkeypox
August 16, 2022
China to discourage abortions to boost low birth rate
August 16, 2022
Newly launched U.S. drugs head toward record-high prices in 2022
August 16, 2022

About Reuters
About Reuters
Reuters News Agency
Brand Attribution Guidelines
Reuters Leadership
Reuters Fact Check
Reuters Diversity Report
Stay Informed
Download the App
Information you can trust
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Follow Us
Thomson Reuters Products
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Refinitiv Products
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
Advertise With Us
Advertising Guidelines
Terms of Use
Digital Accessibility
Site Feedback

All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All rights reserved
My ViewFollowingSaved